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ABSTRACT
Between 2002 and 2004, panels of amniotic ﬂuid
containing varying concentrations of Toxoplasma
gondii were sent to up to 23 laboratories in France
for molecular (PCR-based) detection as part of a
national quality assurance initiative in the
molecular prenatal diagnosis of toxoplasmosis.
Participants were free to enrol and no fees were
required. The general level of sensitivity was
high, and the rate of false-positive reactions was
relatively low. Considerable diversity among PCR
methods and primers was revealed. This external
quality assurance scheme provided the opportun-
ity to improve laboratory practice and perform-
ance, and to increase communication among
laboratories involved in making this diagnosis.
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Toxoplasmosis is an endemic protozoan disease
of great public health importance because of
possible vertical transmission from an infected
woman to a foetus during pregnancy. Prenatal
diagnosis of congenital toxoplasmosis has im-
proved the prognosis and outcome for infected
children considerably wherever it has been
implemented. Prenatal diagnosis has been a
national policy in France since 1978 [1]. PCR-
based molecular diagnostic tests using amniotic
ﬂuid (AF) have largely superseded more classi-
cal methods, and have eliminated the need for
cordocentesis [2]. However, all PCR assays used
for this application are currently in-house meth-
ods established independently in each laborat-
ory. This is known to lead to considerable
variation in diagnostic performance. Accord-
ingly, with a view to improving and standard-
ising prenatal diagnosis at a national level, an
external quality assessment (EQA) scheme was
established during 2002 in France, under the
auspices of the national association of hospital
practitioners and teachers in parasitology–
mycology (ANOFEL). This EQA was repeated
in 2003 and 2004. Participating laboratories were
free to enrol, anonymity of results was guaran-
teed, and no fees were required for participa-
tion. The number of participants in the scheme
increased from 21 in 2002 to 23 in 2004. The test
material included negative and positive samples
of AF containing different Toxoplasma concentra-
tions. Only low concentrations were used, (i)
because most diagnostic methods for pathogens
are known to be particularly fallible with low
concentrations of pathogens in the sample [3,4],
and (ii) because it has been established that a
notable proportion of infected AFs contain low
Toxoplasma loads [5].
The test material was based on naturally
infected samples. Signed consent was obtained
from all women from whom the samples were
obtained. Known PCR-positive and PCR-negative
AFs were pooled separately, and the pools
were then tested for the presence of bacterial
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contamination and by Toxoplasma PCR (four and
eight reactions per pool, respectively). The refer-
ence PCR assay used to control negative samples
allowed the detection of 0.5–1 parasites ⁄mL [6].
The negative pool was then used for making
negative control samples, and also for diluting the
positive pool to produce samples with different
Toxoplasma concentrations. Compared with the
more classical method of seeding negative AFs
with Toxoplasma tachyzoites drawn from mouse
ascitis, the method was simple and used naturally
infecting strains, but had the disadvantage of
using thawed samples and of, theoretically, being
less precise in the quantiﬁcation of parasites. In
the present study, parasite concentrations in the
positive pool were estimated by quantitative PCR
in two or three different laboratories before
dilution and distribution.
Depending on the year, panels included two
to ﬁve samples, totalling 245 samples during the
3-year period. Each participant received identical
2-mL samples drawn at the same time from the
same pools. All participants responded, and
results were analysed anonymously. All partici-
pating laboratories used in-house PCR assays.
The DNA extraction methods and PCR primers
used varied considerably among laboratories
(Table 1). The overall results are shown in
Table 2. Sensitivity problems were observed only
for very low parasite concentrations (<10 ⁄mL);
below this threshold, two to four of the 21–23
laboratories reported false-negative results, re-
presenting 6.7% of 134 samples, which is a low
rate of false-negative results. Thus, the overall
level of sensitivity among the participating
laboratories appeared to be high. In comparison,
a study in 1998 reported that 40% of samples
with a concentration of 10 tachyzoites ⁄mL gen-
erated false-negative results [3]. More recently,
an international study involving 33 laboratories
(of which none appear to be included in the
French network) reported 19.5% false-negative
results (vs. 6.7% in the present study) [4]. The
false-negative results in the present study did
not appear to be related to a particular PCR
method (e.g., real-time, DNA target or primer
pair), but can be attributed to technical proﬁ-
ciency, PCR optimisation and laboratory prac-
tices. Identical conclusions were reached by
Kaiser et al. [4].
It should also be noted that no DNA stabiliser
was used at any stage. However, the absence of
Toxoplasma DNA degradation in the samples was
checked: (i) by multiple PCR testing before send-
ing the samples; and (ii) after sending the sam-
ples, by keeping an entire panel at room
temperature for 5 days in the coordinating labor-
atory before DNA extraction and PCR testing.
However, it is possible that an undetectable level
of DNA degradation might contribute to the false-
negative results observed for samples with very
low parasite concentrations (e.g., 2–6 ⁄mL), and in
laboratories with a slightly less sensitive PCR
assay.
Table 1. Overview of the methods and primers used in
the French external quality assessment scheme for molecu-









TNN methodb, 4 Conventional, 12 B1 gene, 17 B22–B23 [12], 6
Commercial kit, 19 Real-time, 13 T1–T4 [13], 2
Qiagenc, 13 LightCycler (Roche), 6 F–R [14], 2
Roched, 4 Applied Biosytems, 4 [5], 2
Epicentree, 1 i-Cycler (BioRad), 1 B5–B6 [15], 1
Not known, 1 Mx4000 (Stratagene), 1 JW58–59 [16], 1
RotorGene (Corbett), 1 Unpublished, 2
Not known, 1




rDNAg, 2 [19], 2
aThe number of DNA targets and primer pairs may differ from that of participants,
as several laboratories used two different PCR methods.
bTNN (Tween–Nonidet–NaOH), a simple DNA isolation method described by
Hohlfeld et al. [20].
cQiagen QIAmp DNA mini-kit.
dRoche HighPure PCR Template Kit.
eEpicentre MasterPure DNA.
fRepetitive non-coding sequence identiﬁed by Homan et al. [17].
gRibosomal DNA gene.
Table 2. Overall results for the molecular detection of
Toxoplasma gondii in the French external quality assessment
in 2002–2004
Date Samplesa n False-positiveb False-negativec
2002 – 21 0
+ (6–10 ⁄mL) 21 4
2003 – 22 1
– 22 1
+ (2–6 ⁄mL) 22 3
+ (10–20 ⁄mL) 22 0
2004 – 23 1
– 23 0
+ (4–8 ⁄mL) 23 1
+ (8–16 ⁄mL) 23 1
+ (30–60 ⁄mL) 23 0
Total – 111 3
+ 134 9
a –, negative sample; +, positive sample (estimated parasite concentration in
tachyzoites ⁄mL; see text).
bNumber of negative samples found to be positive.
cNumber of positive samples found to be negative.
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With regard to speciﬁcity, the cumulative
rate of false-positive results (2.7%; three of 111
samples) was also relatively low in comparison
with other molecular EQA programmes, e.g.,
2–10% [4,7], 11.6% [3], or 35% [8]. However,
their presence stresses the need to constantly
re-evaluate protocols for the prevention of
carryover contamination. The multiplicity of
replicates of negative controls may help to reveal
more contaminations of this type, which tend
to be sporadic in nature. As negative AF sam-
ples were drawn from women who had sero-
converted during pregnancy, an alternative
explanation for false-positive results could
involve the presence of extremely low concen-
trations of parasites in these samples that would
go undetected by most participants. Assuming
that most Toxoplasma PCR assays have a median
sensitivity of c. 5, or 1–10, parasites ⁄mL [6,9],
parasite concentrations giving such results would
be <5 ⁄ 44–46 mL, i.e., approximately <1 parasi-
te ⁄ 10 mL, which is feasible from the pathophy-
siological viewpoint. However, this seems
unlikely, as a 1-year follow-up of the infants of
these infected women did not reveal congenital
infection after birth.
The overall performance of this national net-
work was better than that reported by three
previous international inter-laboratory evalua-
tions [3,4,10]. In particular, the most recent
evaluation [4] reported correct results in the
entire panel for only 42.1% of datasets, com-
pared with 95.1% in the present study. It is
noteworthy that the laboratories which provided
incorrect results in the present EQAs were
different on each occasion, indicating the likely
absence of major systematic faults during the
diagnostic process in a particular laboratory.
This correlates well with the absence of any
association between the methods used and false-
negative or false-positive results, as noted previ-
ously [4]. This also highlights the need for
constant evaluation and vigilance in all diagnos-
tic laboratories using PCR. Finally, it is import-
ant to stress that this EQA scheme, as well as the
way in which it was conducted, had positive
consequences for molecular diagnosis of toxo-
plasmosis in France. First, it may have improved
the general detection level, in view of the
decrease over the 3-year period in the rate of
false-negative results from 19% (4 ⁄ 21) to 4%
(1 ⁄ 23), for parasite concentrations of <10 ⁄mL.
Second, recommendations made after each EQA
led to an increase in ‘approved’ practices for
molecular diagnosis. Third, it has encouraged
a new spirit of communication and exchange
among the French laboratories involved in
making this diagnosis.
In recent years, several inter-laboratory com-
parative studies have been described for the
molecular diagnosis of toxoplasmosis [3,4,10,11].
All of these studies underlined the urgent
need for standardisation of PCR protocols
and, in this context, the conclusions of Pelloux
et al. [3] remain remarkably topical. The pre-
sent national scheme in France is a ﬁrst and
necessary step towards this difﬁcult goal.
Standardisation of quantitative PCR methods
and results should also be included in view of
the growing number of laboratories using such
methods.
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ABSTRACT
The plasma concentrations of granzymes are
considered to reﬂect the involvement of cytotoxic
T-cells and natural killer cells in various disease
states. Interferon (IFN)-c-inducible protein-10 (IP-
10) and monokine induced by IFN-c (Mig) are
members of the non-ELR CXC chemokine family
that act on T-cells and natural killer cells. This
study revealed that the plasma concentrations of
granzyme B (but not granzyme A), IP-10 and Mig
were higher in 44 Thai patients with deﬁnite or
possible leptospirosis than in healthy blood
donors. These data suggest that activation of
cell-mediated immunity is part of the early host
response to leptospirosis.
Keywords Cell-mediated immunity, chemokines,
granzymes, host reponse, leptospirosis
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Leptospirosis is caused by pathogenic spirochaetes
of the genus Leptospira, and is probably the world’s
most widespread zoonosis [1]. Cytotoxic T-cells
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